From Spinal Taps to Blood-Based Biomarkers: Advances in Alzheimer’s Testing

In this edition of Clinical Lab Chat, CLP’s Director of Business Intelligence, Chris Wolski, interviews Alessio Travaglia, PhD, PMP, director, Translational Science, Neuroscience, at the Foundation for the National Institutes of Health (FNIH).

The wide-ranging interview tackles all aspects of Alzheimer’s testing and treatment, including:

Why traditional methods of Alzheimer’s testing are expensive, invasive, and limit access.
The benefits of blood-based biomarkers for Alzheimer’s diagnosis.
How better diagnostics will benefit patients.
Why we’re on the cusp of a new golden age of neurology
How more biomarkers fuel not only better diagnostics but better treatments.

Poddgruvan

From Spinal Taps to Blood-Based Biomarkers: Advances in Alzheimer’s Testing

Advancements in HLA Matching and Antibody Detection

What Do the New ASCCP Guidelines Mean for Clinical Labs?

Alpha-Synuclein: Adding Precision to Neurodegenerative Testing

C Diff: How Awareness Improves Diagnostics and Treatments

HPV Self-Sampling Is Being Put into Practice in Texas

Will HPV Self-Collection Help Prevent Cervical Cancer?

How Blood-Based Biofluid Testing Is Revolutionizing Cancer Diagnostics

It’s Simple: Point-of-Care Testing Improves Access

How You Can Harness AI in Your Laboratory

Kids and Science: Is this THE Recipe for Solving the Laboratorian Shortage?